Measured Wealth Private Client Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
Other funds holding JAZZ
Measured Wealth Private Client Group's JAZZ Position: Q3 2026 in Review
Measured Wealth Private Client Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 2.1% in Q3 2026, selling an estimated $18.5K and leaving 3,544 shares worth $821K. The position accounts for 0.21% of the portfolio, ranked #71.
Measured Wealth Private Client Group first reported a position in JAZZ in Q1 2025 and has held it in 7 quarters since. The position peaked at $872K in Q2 2026. 672 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.
- Measured Wealth Private Client Group held 3,544 shares of Jazz Pharmaceuticals worth $821K as of Q3 2026.
- Measured Wealth Private Client Group sold 75 Jazz Pharmaceuticals shares in Q3 2026, an estimated $18.5K.
- Jazz Pharmaceuticals made up 0.21% of Measured Wealth Private Client Group's portfolio in Q3 2026, its #71 holding.
- Measured Wealth Private Client Group first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
- Measured Wealth Private Client Group's Jazz Pharmaceuticals position peaked at $872K in Q2 2026.
- 672 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.
Based on Measured Wealth Private Client Group's 13F filing for Q3 2026, filed 10 Nov 2026.